VYGR biotech catalysts & pipeline

VOYAGER THERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

VY7523 — Initial data

Q4 2026

including our plans to generate initial data from the Phase 1 multiple ascending dose clinical trial of VY7523 in early Alzheimer's disease patients in the fourth quarter of 2026 and to initiate and begin dosing patients in a clinical trial of VY1706 in the fourth quarter of 2026 and generate initial acute safety data and initial cerebrospinal fluid tau biomarker-based data in early 2027 and the second half of 2027, respectively;

Source filing

VY1706 — Initial data

early 2027

including our plans to generate initial data from the Phase 1 multiple ascending dose clinical trial of VY7523 in early Alzheimer's disease patients in the fourth quarter of 2026 and to initiate and begin dosing patients in a clinical trial of VY1706 in the fourth quarter of 2026 and generate initial acute safety data and initial cerebrospinal fluid tau biomarker-based data in early 2027 and the second half of 2027, respectively;

Source filing

VY1706 — Initial data

H2 2027

including our plans to generate initial data from the Phase 1 multiple ascending dose clinical trial of VY7523 in early Alzheimer's disease patients in the fourth quarter of 2026 and to initiate and begin dosing patients in a clinical trial of VY1706 in the fourth quarter of 2026 and generate initial acute safety data and initial cerebrospinal fluid tau biomarker-based data in early 2027 and the second half of 2027, respectively;

Source filing

Explore the free biotech catalyst calendar